SCHEDULE 13G/A: Deep Track Capital Discloses 7.15% Passive Stake in Structure Therapeutics Inc.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a 7.15% beneficial ownership stake in Structure Therapeutics Inc., totaling 12.3 million ordinary shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of 12,300,000 Ordinary Shares of Structure Therapeutics Inc.
• This aggregate amount represents 7.15% of Structure Therapeutics Inc.'s outstanding Ordinary Shares.
• The calculation of the percentage is based on 172,028,543 Ordinary Shares outstanding as of January 31, 2025, as reported in the issuer's 10-K filing on February 27, 2025.
• The 12,300,000 ordinary shares include 4,100,000 American Depositary Shares (ADSs), with each ADS convertible into three ordinary shares.
• The Reporting Persons share both voting and dispositive power over all 12,300,000 shares.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the perceived sentiment of the company's operational performance. The presence of a significant institutional investor can be seen as a neutral to slightly positive signal.

Positives

• A significant institutional investor, Deep Track Capital, holds a substantial 7.15% stake in Structure Therapeutics Inc., indicating confidence in the company's long-term prospects from a passive investment perspective.

Risks

• The document does not explicitly detail risks related to the issuer's operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.

Industry Context

This filing indicates a significant passive investment by a specialized biotechnology investment firm in Structure Therapeutics Inc., a company operating in the biotechnology sector. Such investments are common for funds seeking exposure to growth opportunities within specific industries.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may be viewed positively, potentially increasing investor confidence or market liquidity for Structure Therapeutics Inc. shares.

Key Dates

Keywords

Structure Therapeutics Inc., Deep Track Capital, Beneficial Ownership, Schedule 13G, SEC Filing, Ordinary Shares, American Depositary Shares, Biotechnology, Investment Fund, Passive Investment